Evogene Ltd. (EVGN) - NYSE
  • Thu, Jun. 23, 8:58 AM
    • Potash Corp. (NYSE:POT) +3.2% and Mosaic (NYSE:MOS) +2.6% premarket following reports that Belarus may cooperate with Russian potash producer Uralkali for the first time since a dispute ended the alliance between the world's two biggest potash producers in 2013, triggering a fall in global prices that have not yet fully recovered.
    • Belarus Pres. Lukashenko hinted at cooperation during an event in Minsk but did not discuss his conditions; the previous joint venture was based in Minsk, at that time a crucial condition for Belarus and the main concern for Uralkali.
    • Lukashenko also said Belaruskali had signed a new potash supply contract with India, although the company later said it was still finalizing the deal; aside from Belaruskali and Uralkali, POT, MOS and Germany's K+S (OTCQX:KPLUY) supply potash to India.
    • Other relevant tickers: AGU, CF, IPI, ICL, CNHI, SQM, UAN, IPHS, EVGN
    | Thu, Jun. 23, 8:58 AM | 5 Comments
  • Thu, May 19, 8:35 AM
    • Evogene (EVGN) Q1 results: Revenues: $2M (-25.9%); Operating Expense: $5.1M (+2.0%); Operating Loss: ($4.6M) (-12.2%); Net Loss: ($3.4M) (-1.2%); Loss Per Share: ($0.13) (unch); Quick Assets: $98.8M (-11.9%).
    • No guidance given.
    | Thu, May 19, 8:35 AM
  • Thu, May 19, 7:05 AM
    • Evogene (NYSE:EVGN): Q1 EPS of -$0.13 misses by $0.02.
    • Revenue of $2.02M (-25.2% Y/Y) misses by $2.48M.
    • Press Release
    | Thu, May 19, 7:05 AM
  • Tue, Mar. 1, 7:11 AM
    • Evogene (NYSE:EVGN): Q4 EPS of -$0.22 misses by $0.05.
    • Revenue of $2.46M (-32.4% Y/Y) misses by $1.44M.
    • Press Release
    | Tue, Mar. 1, 7:11 AM
  • Dec. 28, 2015, 12:40 PM
    | Dec. 28, 2015, 12:40 PM | 4 Comments
  • Dec. 22, 2015, 7:19 AM
    • Evogene (NYSE:EVGN) appoints Eyal Leibovitz as Chief Financial Officer effective January 1, replacing the departing Sigal Fattal. He joins the firm from N-trig Ltd. where he was also CFO.
    | Dec. 22, 2015, 7:19 AM
  • Nov. 18, 2015, 7:17 AM
    • Evogene (EVGN +3.8%) Q3 results: Revenues: $3.3M (+3.1%); R&D Expense: $3.1M (-16.2%); SG&A: $1M (+2.0%); Operating Loss: ($3.8M) (+11.6%); Net Loss: ($3.4M) (+19.0%); Loss Per Share: ($0.13) (+23.5%); Quick Assets: $106.4M.
    • No guidance given.
    | Nov. 18, 2015, 7:17 AM
  • Nov. 18, 2015, 7:11 AM
    • Evogene (NYSE:EVGN): Q3 EPS of -$0.13 beats by $0.02.
    • Revenue of $3.31M (+4.7% Y/Y) misses by $0.19M.
    | Nov. 18, 2015, 7:11 AM
  • Aug. 5, 2015, 7:09 AM
    • Evogene (NYSE:EVGN): Q2 EPS of -$0.20 misses by $0.01.
    • Revenue of $2.66M (-30.9% Y/Y) misses by $1.74M.
    | Aug. 5, 2015, 7:09 AM
  • Aug. 4, 2015, 7:42 AM
    • Rehovot, Israel-based Evogene (NYSE:EVGN), a computational genomics company focused on improving crop productivity and economics for the food and feed industries, completes the first computational discovery round for microbial genes that have potential to control crop-destroying insects from the families Coleoptera (beetles/weevils) and Lepidoptera (butterflies/moths), including the corn rootworm and corn earworm.
    • The discovery round utilized the company's proprietary microbial database and a dedicated analysis platform called BiomeMiner. The candidate genes will be validated against target insects at its R&D site in St. Louis, MO. The work should be finished next year.
    • The current market for insect control traits based on microbial genes is ~$4.5B annually. The insecticidal genes are inserted into a target crop where they provide protection against certain harmful insects. Most of the current microbial gene-based products are derived from the bacterium Bacillus thuringiensis, which insects have grown resistant to over the years.
    | Aug. 4, 2015, 7:42 AM
  • May 19, 2015, 7:46 AM
    • Evogene (EVGN -1.3%) Q1 results: Revenues: $2.7M (-30.8%); COGS: $1.8M (-30.8%); R&D Expense: $3.5M (+29.6%); SG&A: $1M (+11.1%); Operating Loss: ($4.1M) (-57.7%); Net Loss: ($3.4M) (-47.8%); Loss Per Share: ($0.13) (-44.4%); Quick Assets: $112.2M (-1.2%).
    • No guidance given.
    | May 19, 2015, 7:46 AM
  • May 19, 2015, 7:11 AM
    • Evogene (NYSE:EVGN): Q1 EPS of -$0.13 beats by $0.07.
    • Revenue of $2.7M (-30.1% Y/Y) misses by $0.95M.
    | May 19, 2015, 7:11 AM
  • Feb. 26, 2015, 7:36 AM
    • Evogene (NYSE:EVGN): Q4 EPS of -$0.19 misses by $0.13.
    • Revenue of $3.64M (-17.5% Y/Y) misses by $0.16M.
    | Feb. 26, 2015, 7:36 AM
  • Feb. 9, 2015, 7:50 AM
    • Israeli biotech Evogene Ltd. (NYSE:EVGN) signs a letter of intent to establish a research and development operation on the campus of the Donald Danforth Plant Science Center in St. Louis. The $10M 6,000 sq. ft. facility will house the firm's efforts on advanced solutions for insect control. James Presnail, Ph.D., will lead the organization, expected to be up and running by the end of this year.
    | Feb. 9, 2015, 7:50 AM
  • Nov. 10, 2014, 8:17 AM
    • Evogene (NYSE:EVGN): Q3 EPS of -$0.17 misses by $0.06.
    • Revenue of $3.16M (-25.3% Y/Y) misses by $1.05M.
    | Nov. 10, 2014, 8:17 AM
  • Oct. 22, 2014, 12:04 PM
    • Evogene (EVGN -0.1%) will report Q3 results on November 10 before the open. The conference call will begin at 9:30 am ET.
    • Consensus view is a loss of ($0.11) on revenues of $4.2M.
    | Oct. 22, 2014, 12:04 PM
Company Description
Evogene Ltd. operates as a plant genomics company. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. It also offers a solution for crop productivity improvement through biotechnology and breeding using a technology infrastructure... More
Sector: Healthcare
Industry: Biotechnology
Country: Israel